BioCentury | Oct 1, 2020
Finance

Sonoma tops off series A as it builds broader Treg therapy pipeline

With an extra $30 million in series A funding, Sonoma is expanding the range of indications for its immunosuppressive Treg cell therapy pipeline, and exploring combination strategies that account for the immune system’s complexity. The...
BioCentury | Sep 30, 2020
Deals

As China’s CStone preps for launches, Pfizer buys equity stake and local rights to PD-L1 program

A deal giving Pfizer local rights to CStone’s PD-L1 inhibitor will add at least $200 million to the Suzhou-based biotech’s balance sheet as it prepares for a series of drug approvals, while taking advantage of...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Islet-like organoids expressing PD-L1 for diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Pancreatic islet-like organoids overexpressing PD-L1 and derived from human induced pluripotent stem cells (iPS cells) could be used to treat Type I diabetes. The organoids were generated by engineering human...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint blockade. In...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 25, 2020
Product Development

Antibody, T cell responses for J&J COVID-19 vaccine support Phase III dose and regimen

Interim Phase I/II data for J&J’s COVID-19 vaccine show its ability to induce neutralizing antibodies via a single immunization is maintained in the elderly, like Moderna’s candidate, and demonstrates...
BioCentury | Sep 23, 2020
Product Development

Immunomedics data point to Trodelvy’s $21B potential

New data from Immunomedics suggest its antibody-drug conjugate Trodelvy is on track for the label expansions worked into Gilead’s $21 billion takeout price for the biotech. At the European Society for Clinical Oncology Virtual Congress,...
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Priority Review for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb Co. (NYSE:BMY) suggests that an approval decision could come before...
BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

Amgen’s leading KRAS inhibitor hasn’t maintained the exceptionally high response rates seen in its earliest readouts, but the first longer-term data for AMG 510 start to answer one of the biggest questions...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCACIncyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and a disease control rate of 49% in the...
Items per page:
1 - 10 of 12553